DARA owners acquire troubled Point Therapeutics

DARA BioSciences is buying out Point Therapeutics, which stumbled badly after the FDA put its cancer therapy, talabostat, on hold. Wellesley, MA-based Point Therapeutics, which was facing a de-listing, had already slashed its workforce in an effort to cut costs. In the merger deal, DARA stockholders will own 96.4 percent of the new company, which will be called DARA and will be based in Raleigh.

- check out the release on the deal
- here's the report from the Boston Business Journal

Read more on: Point Therapeutics

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.